Evogenom
Not stated, EU · 10 employees on LinkedIn · 4 known investors
Evogenom provides genetic testing and personalized wellness insights based on DNA analysis, delivered through a mobile app with an AI wellness coach. The service helps consumers understand how their genetics affect nutrition, exercise, sleep, and recovery to optimize their daily habits.
Also known as Evogenom Oy
Investors · 4
Also in the syndicate · 3
Company profile
researched Aug 2026Evogenom Oy is a Finnish consumer genetics company based in Jyväskylä that sells at-home saliva DNA tests and delivers the results through a mobile app. Customers provide a 2 ml saliva sample by post, the sample is analysed by a certified lab, and results appear in the Evogenom app roughly 2-4 weeks after receipt (the website elsewhere states 4-8 weeks end to end). The company states it analyses over 625,000-650,000 wellness-related genetic variants (SNPs) covering nutrition, weight, fitness, sleep, stress, recovery and, per press coverage, medication, with insights referenced to large-scale scientific studies.
Products are organised into gendered product lines, EvoFemme and EvoHomme, each with themed "Systems" such as Energy & Balance, Nutrition/Fuel & Weight, Fitness/Strength & Performance, Resilience & Recovery and Perimenopause, plus Complete Nutrition and Complete Training Blueprints. Each System includes 22 or more insights; the site advertises 70+ insights in total. The DNA genotyping is performed once, and additional Systems or add-ons unlock instantly in the app without a new sample. All results are paired with EvoCoach, an AI wellness coach that combines genetic findings with the user's goals and habits to produce routines, reminders and progress tracking.
The company emphasises data protection: data is stored in Finland, genetic data and personal identifiers are kept separate, samples are destroyed four months after analysis, genetic data is retained only with consent for a maximum of five years, and data is not sold or shared with third parties or used in research without explicit consent.
Founding story
According to the company, Evogenom's story began in 2017 in Jyväskylä, Finland, when a group of entrepreneurs, researchers, athletes and genetics experts set out to reduce guesswork in well-being. The team worked closely with experts at the University of Jyväskylä's sport and exercise science faculty to explore how genetics explain differences in training, nutrition and recovery. Early projects with sports teams and athletes led the founders to broaden the focus from elite sport to everyday consumer wellness. A separate press report states the company was founded in 2016.
Business model
Direct-to-consumer sale of at-home DNA test kits with app-delivered results. The first test, priced at €199, includes one-time DNA genotyping, a System of 22+ insights and access to the EvoCoach AI coach. Complete Blueprints are priced at €249. Because the genotype is stored, customers can buy further insight packages inside the app at €29-199 without submitting a new sample.
Revenue comes from one-off purchases of DNA test Systems and Blueprints (€199-249) and from subsequent in-app purchases of additional insight packages and add-ons ranging from €29 to €199; gift cards are also sold.
Traction
The company's website states it has thousands of users. No further verified operating metrics are stated.
Latest developments
In October 2024 Evogenom announced a funding round with Trind VC/Trind Ventures and additional investors and business angels, earmarked for sales, internationalisation, product portfolio development and market position. Antti Seppä was appointed Chairman of the Board in May 2024.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned as a Nordic consumer genetic testing provider combining scientific accuracy with user-friendliness, differentiating on data residency in Finland/the EU and on AI-driven coaching rather than static reports. Company and investor statements cite growth in the genetic testing market and international scalability potential.
Combination of one-time genotyping with expandable in-app insight packages, an empathetic AI coach (EvoCoach) that converts genetic results into daily actions, university and sports-genetics research roots, an in-house genotyping chip and analysis software, and a privacy model with Finnish data storage, separated identity data, sample destruction and no third-party data sharing.
Technology
At-home saliva collection kits analysed by a certified laboratory using SNP genotyping of 625,000+ (stated elsewhere as over 650,000) wellness-related genetic markers, with interpretations drawn from 1,500+ GWAS studies. Press coverage reports the company has developed its own genotyping chip and software for complex trait-genetics analyses. Results are delivered in a mobile app together with EvoCoach, an AI wellness coach that links genetic results and user habits into routines, nudges and plans, plus a habit-change system with reminders and progress tracking. Processing occurs within a closed, encrypted system with access controls.
Go-to-market
Online direct-to-consumer sales through the company's own web shop and app, supported by customer testimonials, gift cards and add-on upsells within the app. The 2024 funding was stated to be for strengthening sales and internationalisation.
Consumers seeking personalised guidance on nutrition, weight, energy, sleep, stress, exercise and recovery, segmented into female (EvoFemme, including perimenopause) and male (EvoHomme) product lines, spanning everyday wellness users through to people training for performance. The company originally worked with athletes and sports teams.
Geography
Headquartered in Jyväskylä, Finland, with data stored in Finland/the EU; the website ships kits internationally and the company has stated internationalisation ambitions.
History
The company originated from work with the University of Jyväskylä and sports teams before expanding from elite sports into consumer wellness. In May 2024 the Board of Directors appointed Antti Seppä, CEO of Docue and former CEO of Admicom Oyj, as Chairman. In October 2024 the company announced a funding round including Trind VC (Trind Ventures) and a group of other investors and business angels, intended to support sales, product development, market position and international expansion.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsEvogenom Oy announced it had secured significant funding from Trind VC (Trind Ventures) together with a group of other investors and business angels. CEO Hannu Tolvanen said the funding supports sales, internationalisation and product portfolio development. The amount was not disclosed.
The Board of Directors of Evogenom Oy appointed Antti Seppä, CEO of Docue and former CEO of Admicom Oyj, as its new Chairman.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- Evogenomevogenom.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Evogenom do?
- Finnish consumer genetics company selling at-home DNA wellness tests with an AI coach app that turns results into daily habits.
- Who are Evogenom's investors?
- Evogenom's investors include Trind Ventures.
- Where is Evogenom headquartered?
- Evogenom is headquartered in Not stated, EU.